key: cord-1000384-5hy4v5zi
authors: Alberca, Gabriela Gama Freire; Alberca, Ricardo Wesley
title: COVID‐19‐vaccinated plasma treatment for COVID‐19 patients?
date: 2021-03-14
journal: Influenza Other Respir Viruses
DOI: 10.1111/irv.12852
sha: d542dada6e5d774becfa78c301c8e514b34c7dd0
doc_id: 1000384
cord_uid: 5hy4v5zi

nan

Since the beginning of the pandemic, passive immunization with plasma derived from patients recovered from COVID-19 has been used as a virus-specific therapeutic intervention. A recent randomized trial with 288 patients hospitalized with severe COVID-19 pneumonia verified no significant differences in the clinical status or mortality in the treatment with placebo or convalescent plasma. 3 A possible explanation is that the levels of neutralizing antibodies and the duration that anti-SARS-CoV-2 antibodies levels remain high for a very short period after natural infection and antibody production is dependent on the severity of the infection. 4 Therefore, these factors may affect the efficiency of the treatment with convalescent plasma. Alternatively, the usage of anti-SARS-CoV-2 monoclonal antibodies to treat COVID-19 patients presented promising results, but it may be limited by the costs and production capacity. 5 With the beginning of the vaccination process worldwide, we would like to propose an alternative to the convalescent plasma: the vaccinated plasma.

With the vaccination process, the numbers of cases and deaths by COVID-19 are expected to drop, once "herd immunity" is established. Nevertheless, due to the limitations of the overall production and distribution of the vaccines, this process could take years. Therefore, due to the current health, economic and social disruption caused by the pandemic 6,7 investigating treatments for COVID-19 patients is a necessary process. 8, 9 Vaccination produces a safe and effective immune response to COVID-19, with high titers of neutralizing anti-SARS-CoV-2 IgG antibodies. 10 Therefore, the use of vaccinated plasma could present an important, safe, and more effective intervention in comparison with convalescent plasma. Indeed, the effectiveness of this procedure still needs to be investigated, as well as proper dosage and timing of the plasma transfer in relation to the infection day. Nevertheless, we believe that this could represent a promising strategy in the current pandemic situation, which should be discussed by the audience of this prestigious journal.

This work was supported by Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) Grant: 19/02679-7.

All authors have no conflicts of interest to declare. 

The peer review history for this article is available at https://publo ns.com/publo n/10.1111/irv.12852. 

What is the long-term clinical significance of anti-SARS-CoV-2-specific IgG? Influenza Other Respi Viruses

Human post-infection serological response to the spike and nucleocapsid proteins of SARS-CoV-2. Influenza Other Respi Viruses

A randomized trial of convalescent plasma in Covid-19 severe pneumonia

Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies

Horses for courses? Assessing the potential value of a surrogate, point-of-care test for SARS-CoV-2 epidemic control

Population anxiety and positive behaviour change during the COVID-19 epidemic: Cross-sectional surveys in Singapore, China and Italy

Frequencies of CD33+ CD11b+ HLA-DR-CD14-CD66b+ and CD33+ CD11b+ HLA-DR-CD14+ CD66b-cells in peripheral blood as severity immune biomarkers in COVID-19

Perspective: the potential effects of naringenin in COVID-19

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial